Close Menu

NEW YORK (GenomeWeb) – Investment bank Canaccord Genuity said today that it has initiated coverage of liquid biopsy firm Guardant Health with a Buy rating and a price target of $90.

In a note to investors, analyst Mark Massaro said that he views Guardant as the leader in liquid biopsy cancer testing, adding that that stock gains so far have been justified and predicted that its shares will rise further. He estimated that the Guardant360 test is less than 5 percent penetrated in a $6 billion market for liquid biopsy therapy selection in advanced cancer patients.  

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.